# NARLAL2 (NCT02354274)

> Novel Approach to Radiotherapy in Locally Advanced Lung Cancer Concomitant Navelbine®

No report yet. It can be ordered.

- Drugs tested: none (the trial tests no drug)
- Indication: locally advanced non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02354274
- Phase: NA
- Status: RECRUITING
- Sponsor: Olfred Hansen
- Conditions: NSCLC
- Interventions: Escalated: Inhomogeneous dose plan; Standard: Homogeneous dose plan
- Enrollment: 330
- Primary outcome: Locoregional control (Tumor recurrency is assessed by scheduled CT (of the thorax and upper abdomen)

## Indexed commentary on NARLAL2 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 14 posts on X

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=narlal2-nct02354274

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02354274", "email": "<work email>"}; the inbox owner confirms by the emailed link.